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mediated metabolic tumor effects using in vivo achievable 
biguanide concentrations. 
Materials and Methods: Initially we developed 11C labeled 
MET, which allowed assessment of in vitro cellular drug 
uptake and, importantly, in vivo biodistribution assessment 
using PET scans or organ dissection in tumor-bearing mice. 
Based on those results cellular effects of physiologically 
relevant doses of biguanides were tested in 14 cell lines using 
assays of proliferation/viability, glucose metabolism (FDG 
retention), respiration and lactic acid production 
(extracellular flux analyzer) and stress signaling. 
Finally, the two tumor models SiHa (cervix) and A549 (lung) 
were established in mice to assess acute and long-term 
metabolic, microenvironmental and anti-proliferative effects 
of PHEN treatment. 
Results: In vivo results showed that [MET] in blood peaked at 
250 μM in mice administered maximum tolerable dose (250 
mg/kg). Furthermore, MET was retained by tumor cells in 
vitro as well as in vivo, and uptake could be blocked by 
unlabeled MET suggesting involvement of OCTs. MET uptake 
varied widely among cell lines, with the highest uptake in 
A549. Likewise, inhibition of respiration and stimulation of 
glucose use and cell viability/proliferation was mostly 
affected in cell lines with high MET uptake. Even so, most 
cell lines were insensitive to in vivo achievable MET 
concentrations. PHEN was 100 times more potent than MET 
and induced profound metabolic changes at 50 μM in all cell 
lines, and down to a physiological relevant concentration of 1 
μM in A549. In accordance, PHEN was chosen for further 
testing in tumor-bearing mice. Data analysis of tumor 
microenvironment (hypoxia) and growth is ongoing.  
Conclusions: Biguanides affect cellular energy metabolism 
and proliferation in vitro but metabolic effects of MET were 
typically restricted to non-physiological concentrations and 
MET retention and sensitivity varied significantly among cell 
lines. PHEN exerted similar effects as MET but with greater 
potency and may affect a broader selection of tumors at 
physiologically achievable concentrations. Labeling of 
biguanides may allow PET-based identification of patients 
with treatment-responsive tumors. 
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Purpose/Objective: Carbon ions (12C-ions) show an increased 
relative biological effectiveness (RBE) relative to photons. To 
compare the impact of intra- and intertumor heterogeneity 
on the RBE, dose-response curves for photons and 12C-ions 
were determined for three sublines of a syngeneic rat 
prostate adenocarcinoma. 
Materials and Methods: Fresh tumor fragments from three 
sublines (AT1, HI and H) of the Dunning prostate tumor R3327 
were transplanted subcutaneously into the distal right thigh 
of male Copenhagen rats. Tumors were treated once with 
increasing single doses of either 12C-ions or 6 MeV photons. 
Primary endpoint was local tumor control within 300 days. 
For the H-tumor, histological tumor control, defined as 
absence of proliferation (BrdU-injection) in the remaining 
fibrotic nodules (Hematoxylin/Eosin staining) was used as 
secondary endpoint. RBE-values were calculated by the ratio 
of TCD50-values (dose to achieve 50% tumor control 
probability) for photons and 12C-ions, respectively. 
Results: Local tumor control can be achieved with 12C-ions 
and photons in all three sublines. For all tumors an increased 
effectiveness of 12C-ions was observed. The RBE for local 
tumor control increased from 1.62 ± 0.11 (H) to 2.08 ± 0.13 
(HI) to 2.30 ± 0.08 (AT1). Using histological tumor control, 
the RBE for the H-tumor increased to 1.80 ± 0.13. For 12C-ion 
irradiations the variation of TCD50-values between tumor 
sublines was significantly smaller than after photon 
irradiation. Additionally 12C-ion dose-response curves were 
much steeper compared to photons indicating a smaller 
intratumor heterogeneity for 12C-ions. 
Conclusions: The study confirms the increased relative 
biological effectiveness of 12C-ions in tumors, which is the 
highest for the highly radioresistant AT1-tumor and the 
smallest for the well-differentiated H-tumor. The very 
heterogeneous moderately differentiated HI-tumor lies in 
between. This indicates a clear correlation between 
decreasing differentiation status and increasing RBE. 12C-ions 
may therefore be beneficial especially in undifferentiated 
tumors, with a high photon resistance. Changes of RBE with 
tumor differentiation were predominantly caused by changes 
in the photon response. This supports the assumption that 
the response to 12C-ions is less dependent on tumor 
heterogeneity compared to photons. Thus heterogeneities 
within patient populations or the existence of radioresistant 
subpopulations within single tumors may be expected to have 
less impact on the 12C-ions radiation response. The underlying 
differential mechanisms are currently analyzed in ongoing 
histological and functional experiments.  
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